Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases

Olivia Belbin; Sylvain Lehmann; Eduard Sabidó; Christophe Hirtz

doi:10.3389/fnagi.2020.00232

Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases

Front Aging Neurosci. 2020 Nov 26:12:232. doi: 10.3389/fnagi.2020.00232. eCollection 2020.

Authors

Olivia Belbin^{1

2}, Sylvain Lehmann³, Eduard Sabidó^{4

5}, Christophe Hirtz³

Affiliations

¹ Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
² Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
³ IRMB, University of Montpellier, INSERM, CHU Montpellier, (LBPC-PPC), Montpellier, France.
⁴ Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
⁵ Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain.

No abstract available

Keywords: Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; biomarker; drug targets; frontotemporal dementia; neurodegenerative diseases; proteomics.

Publication types

Editorial